Apollomics (NASDAQ:APLM) Shares Down 9% – Time to Sell?

Apollomics, Inc. (NASDAQ:APLM)’s share price was down 9% during trading on Tuesday . The stock traded as low as $8.71 and last traded at $8.80. Approximately 7,185 shares traded hands during trading, a decline of 92% from the average daily volume of 90,982 shares. The stock had previously closed at $9.67.

Apollomics Stock Down 17.1 %

The company has a 50 day moving average of $13.14 and a 200 day moving average of $17.68.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Apollomics stock. Exchange Traded Concepts LLC grew its position in Apollomics, Inc. (NASDAQ:APLM) by 247.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,259,117 shares of the company’s stock after purchasing an additional 896,316 shares during the period. Exchange Traded Concepts LLC owned about 1.41% of Apollomics worth $179,000 at the end of the most recent reporting period. Institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.